Plain-English translation of NCT07382583 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at M.D. Anderson Cancer Center are building a personalized online tool to help women at risk for endometrial cancer understand whether a levonorgestrel-releasing intrauterine system—a small device placed in the uterus that releases a hormone—might be right for them. The tool will help women prepare for conversations with their doctors about cancer prevention and will be available in English and Spanish.
Many women who could benefit from this medication for cancer prevention don't know it exists or understand how it might help them. This study aims to create an educational tool that helps women understand their personal risk and make informed decisions together with their healthcare providers.
You likely qualify if…
You likely don't qualify if…
This study has two phases. In Phase 1, participants will share their thoughts and experiences through interviews to help researchers understand what women and doctors need to know about this medication. In Phase 2, researchers will test a new online tool and gather feedback from women, doctors, and other healthcare providers. Overall, participation involves interviews and discussions about decision-making regarding cancer prevention.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Sponsor
M.D. Anderson Cancer Center
Collaborators
Cancer Prevention Research Institute of Texas
Enrollment target
~270 participants
Started
February 2026
Primary completion
February 2028
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Larissa A Meyer, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.